PERSONALIZED CANCER VACCINES: WHO SHOULD PICK THE TARGET?

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S40, 2014 Special supplement with the abstract book of LATINFARMA 2013 Plenary Lecture PL 005: PERSONALIZED CANCER VACCINES: WHO SHOULD PICK THE TARGET? Overwijk WW. Houston, Texas, USA. Abstract T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual’s … Continue reading PERSONALIZED CANCER VACCINES: WHO SHOULD PICK THE TARGET?

J Pharm Pharmacogn Res 2(Suppl. 1): S40, 2014

Special supplement with the abstract book of LATINFARMA 2013

Plenary Lecture

PL 005: PERSONALIZED CANCER VACCINES: WHO SHOULD PICK THE TARGET?

Overwijk WW.

Houston, Texas, USA.
Abstract

T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual’s cancer cells (the mutanome) encode unique peptides (mpeptides) that can be targets for T cells. The recent advances in nextgeneration sequencing and computation prediction allow, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about this extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. A major question is which peptides to target therapeutically. One approach is to select peptides based on mutation analysis and peptide binding prediction algorithms. Alternatively, we can let the immune system “pick” the target peptide by inducing a tumor microenvironment that promotes T cell priming in vivo. We will present data on both approaches and discuss pros and cons of either approach.

Phyllanthus emblica flavonoid glycosides against xanthine oxidase
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1067-1078, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1959_12.6.1067 Original Article Antioxidant potential and xanthine oxidase inhibition of flavonol glycosides from Phyllanthus emblica L. leaves [Potencial antioxidante e inhibición de la xantina oxidasa de los glucósidos de flavonol de las hojas de Phyllanthus emblica L.] Husnunnisa1, Rika Hartati1, Rachmat Mauludin2, … Continue reading Phyllanthus emblica flavonoid glycosides against xanthine oxidase
Spray-drying Perilla frutescens extract optimization
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1056-1066, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.2009_12.6.1056 Original Article Optimization of spray-drying conditions and quality assessment of dry extract from Perilla frutescens (L.) Britton leaves [Optimización de las condiciones de secado por atomización y evaluación de la calidad del extracto seco de hojas de Perilla frutescens (L.) Britton] … Continue reading Spray-drying Perilla frutescens extract optimization
Honey clinical applications in complementary medicine
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1040-1055, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1870_12.6.1040 Review Honey clinical applications in complementary medicine: A critical review [Aplicaciones clínicas de la miel en la medicina complementaria: Una revisión crítica] Thai Hau Koo1, Andee Dzulkarnaen Zakaria2*, Mohd Zulkifli Mustafa3 1Department of Internal Medicine, School of Medical Sciences, Universiti Sains … Continue reading Honey clinical applications in complementary medicine

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio